[
  {
    "ts": null,
    "headline": "Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus",
    "summary": "NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.",
    "url": "https://finnhub.io/api/news?id=a43a37cd0dcbd36152114259bd1ec98a3f75b3bc8b425fb159f6dabfbce7a1e8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754666340,
      "headline": "Intellia Q2 Loss Narrower Than Expected, Pipeline Progress in Focus",
      "id": 136276559,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "NTLA posts narrower Q2 loss and beats on revenues, while advancing phase III studies for ATTR and HAE programs.",
      "url": "https://finnhub.io/api/news?id=a43a37cd0dcbd36152114259bd1ec98a3f75b3bc8b425fb159f6dabfbce7a1e8"
    }
  },
  {
    "ts": null,
    "headline": "BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform",
    "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock to $640 from $600, while keeping an “Outperform” rating, as reported by The Fly. As per the analyst, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s healthy Q2 2025 […]",
    "url": "https://finnhub.io/api/news?id=b6c6b757f1819a27d747bdc299bdb54cf4030d17a68ead99a65f10417705d335",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754624911,
      "headline": "BMO Capital Lifts PT on Regeneron Pharmaceuticals (REGN) Stock, Keeps Outperform",
      "id": 136267376,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "REGN",
      "source": "Yahoo",
      "summary": "Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the Most Undervalued Long Term Stocks to Buy According to Hedge Funds. On August 4, BMO Capital lifted the price target on the company’s stock to $640 from $600, while keeping an “Outperform” rating, as reported by The Fly. As per the analyst, Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)’s healthy Q2 2025 […]",
      "url": "https://finnhub.io/api/news?id=b6c6b757f1819a27d747bdc299bdb54cf4030d17a68ead99a65f10417705d335"
    }
  }
]